exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089335 RNA Name: hsa-miR-873-5p RNA Type: miRNA Chromosome: chr9 Starnd: - Coordinate: Start Site(bp): 28888925 End Site(bp): 28888945 External Links: hsa-miR-873-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CACUL1 chr10 118674167 118755249 - ICAM1 chr19 10271093 10286615 + IDS chrX 149476988 149521096 - NUDT3 chr6 34279679 34392669 - EPHA4 chr2 221418027 221574202 - TRIOBP chr22 37697048 37776556 + BCL2L11 chr2 111119378 111168445 + SEPHS2 chr16 30443631 30445874 - PFKFB3 chr10 6144934 6254644 + PSD3 chr8 18527303 19084730 - PRDM15 chr21 41798225 41879482 - DLG3 chrX 70444835 70505490 + ORAI1 chr12 121626550 121642677 + LMBR1 chr7 156668946 156893216 - TRIO chr5 14143342 14532128 + OTUB1 chr11 63985853 64001811 + HDGF chr1 156742109 156766925 - FAM222B chr17 28755978 28855232 - TBX3 chr12 114670255 114684175 - BCL9L chr11 118893875 118925608 - CTTNBP2NL chr1 112396214 112463456 + CENPX chr17 82018702 82024107 - SMG5 chr1 156249224 156282825 - PLAGL2 chr20 32192504 32207743 - BICRA chr19 47608196 47703277 + CSNK1E chr22 38290691 38318084 - TMEM179B chr11 62787402 62790400 + DBNDD1 chr16 90004871 90020128 - ZXDB chrX 57591652 57597545 + APPL2 chr12 105173297 105236203 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000417 chr12 69644908 69656342 + hsa_circ_0000987 chr2 30748452 30756180 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC002116.1 chr19 36008638 36014235 - AC079781.5 chr7 97851688 97972985 - AC084809.2 chr17 32905662 32906584 + AC239868.1 chr1 149861271 149862504 + AC245033.4 chr15 82533175 82540008 - AL022311.1 chr22 37876148 37895563 + AL049543.1 chr6 28587378 28591747 + AL355987.2 chr9 136800366 136829466 + GAS5 chr1 173858559 173868882 - LINC01535 chr19 37251885 37265535 + MALAT1 chr11 65497688 65506516 + MIR4435-2HG chr2 111006015 111523376 - MIR503HG chrX 134543119 134546642 - NEAT1 chr11 65422774 65445540 + SNHG15 chr7 44983023 44986961 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.